UBS Group AG Has $2.72 Million Stock Position in USANA Health Sciences, Inc. $USNA

UBS Group AG increased its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 252.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 138,334 shares of the company’s stock after buying an additional 99,063 shares during the period. UBS Group AG’s holdings in USANA Health Sciences were worth $2,715,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allianz Asset Management GmbH raised its stake in USANA Health Sciences by 126.0% during the third quarter. Allianz Asset Management GmbH now owns 47,203 shares of the company’s stock worth $1,300,000 after buying an additional 26,314 shares during the last quarter. National Bank of Canada FI raised its stake in USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after buying an additional 1,201 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in USANA Health Sciences by 19.3% during the fourth quarter. Harbor Capital Advisors Inc. now owns 7,515 shares of the company’s stock worth $148,000 after buying an additional 1,216 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in USANA Health Sciences during the third quarter worth $664,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in USANA Health Sciences during the third quarter worth $266,000. 54.25% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

USNA has been the subject of a number of analyst reports. Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Finally, Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Insiders Place Their Bets

In other USANA Health Sciences news, insider Joshua Foukas sold 3,791 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 5,906 shares of company stock valued at $112,847 in the last ninety days. Insiders own 0.82% of the company’s stock.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $18.38 on Wednesday. The company has a market cap of $339.35 million, a P/E ratio of 39.11, a PEG ratio of 0.74 and a beta of 0.77. The stock has a 50 day simple moving average of $18.24 and a two-hundred day simple moving average of $19.48. USANA Health Sciences, Inc. has a fifty-two week low of $16.60 and a fifty-two week high of $38.32.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. The business had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, research analysts predict that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.